Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat IR
Drug: Febuxostat XR
Drug: Febuxostat placebo
Drug: Colchicine
Drug: Naproxen
Drug: Lansoprazole

First Posted Date: 2014-05-15

Last Posted Date: 2016-11-03

Lead Sponsor: Takeda

Target Recruit Count: 1790

Registration Number: NCT02139046

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"

Completed

Conditions: Breast Cancer

Interventions: Drug: Leuprorelin Acetate

First Posted Date: 2014-05-09

Last Posted Date: 2016-10-18

Lead Sponsor: Takeda

Target Recruit Count: 2816

Registration Number: NCT02134977

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Namilumab
Drug: Placebo

First Posted Date: 2014-05-02

Last Posted Date: 2017-04-07

Lead Sponsor: Takeda

Target Recruit Count: 122

Registration Number: NCT02129777

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

Phase 2

Completed

Conditions: Gout
Moderate Renal Impairment

Interventions: Drug: Febuxostat XR
Drug: Febuxostat placebo
Drug: Febuxostat IR
Drug: Colchicine
Drug: Naproxen
Drug: Lansoprazole

First Posted Date: 2014-05-01

Last Posted Date: 2016-11-03

Lead Sponsor: Takeda

Target Recruit Count: 189

Registration Number: NCT02128490

Locations: 🇺🇸
Benny Green MD PA Family Practice, Little Rock, Arkansas, United States
🇺🇸
Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸
Central Kentucy Reseach Associates, Lexington, Kentucky, United States

and more 8 locations

Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

Phase 1

Completed

Conditions: Ascending Single Dose Study

Interventions: Drug: TAK-438
Drug: Placebo

First Posted Date: 2014-04-28

Last Posted Date: 2014-04-28

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT02123927

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Phase 1

Completed

Conditions: Dose Finding Study

Interventions: Drug: TAK-438
Drug: TAK-438 Placebo

First Posted Date: 2014-04-28

Last Posted Date: 2014-04-28

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT02123953

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Phase 1

Completed

Conditions: Clinical Pharmacology

Interventions: Drug: TAK-233
Drug: Placebo

First Posted Date: 2014-04-14

Last Posted Date: 2014-10-21

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT02113020

A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: TAK-850

First Posted Date: 2014-04-11

Last Posted Date: 2015-07-27

Lead Sponsor: Takeda

Target Recruit Count: 55

Registration Number: NCT02111252

Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -

Completed

Conditions: Osseous Paget's Disease

Interventions: Drug: Sodium risedronate

First Posted Date: 2014-04-08

Last Posted Date: 2019-06-03

Lead Sponsor: Takeda

Target Recruit Count: 315

Registration Number: NCT02106455

36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets

Completed

Conditions: Osteoporosis

Interventions: Drug: Sodium risedronate

First Posted Date: 2014-04-08

Last Posted Date: 2019-07-30

Lead Sponsor: Takeda

Target Recruit Count: 579

Registration Number: NCT02106442

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy